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a  b  s  t  r  a  c  t
Ghrelin  and  its receptor,  the growth  hormone  secretagogue  receptor  (GHS-R),  are expressed  in the  heart,
and  may  function  to promote  cardiomyocyte  survival,  differentiation  and  contractility.  Previously,  we had
generated  a truncated  analog  of ghrelin  conjugated  to  ﬂuorescein  isothiocyanate  for  the  purposes  of deter-
mining  GHS-R  expression  in  situ.  We  now  report  the  generation  and  characterization  of  a  far-red  ghrelin
analog,  [Dpr3(octanoyl),  Lys19(Cy5)]ghrelin  (1–19),  and  show  that  it can  be used to  image  changes  in GHS-
R  in  developing  cardiomyocytes.  We  also  generated  the  des-acyl  analog,  des-acyl  [Lys19(Cy5)]ghrelin
(1–19)  and  characterized  its  binding  to  mouse  heart  sections.  Receptor  binding  afﬁnity  of  Cy5-ghrelin
as  measured  in  HEK293  cells overexpressing  GHS-R1a  was  within  an  order  of magnitude  of  that  of
ﬂuorescein-ghrelin  and  native  human  ghrelin,  while  the des-acyl  Cy5-ghrelin  did  not bind  GHS-R1a.
Live  cell  imaging  in  HEK293/GHS-R1a  cells  showed  cell surface  labeling  that  was  displaced  by  excess
ghrelin.  Interestingly,  Cy5-ghrelin,  but  not  the  des-acyl  analog,  showed  concentration-dependent  bind-
ing in  mouse  heart  tissue  sections.  We  then  used  Cy5-ghrelin  to  track  GHS-R  expression  in P19-derived
cardiomyocytes.  Live  cell  imaging  at different  time  points  after  DMSO-induced  differentiation  showed
that  GHS-R  expression  preceded  that  of  the  differentiation  marker  aMHC  and  tracked  with  the  contrac-
tility  marker  SERCA  2a. Our far-red  analog  of  ghrelin  adds  to the  tools  we  are  developing  to  map  GHS-R
in developing  and  diseased  cardiac  tissues.
© 2014  Published  by  Elsevier Inc.
1. Introduction
Ghrelin is a growth-hormone releasing peptide that mediates its
effects through the growth hormone secretagogue receptor, GHS-
R1a. Knockout mouse models have identiﬁed the importance of
GHS-R signaling in energy homeostasis [12], feeding behavior lead-
ing to body weight control [29] and stressor-induced metabolic
changes [22]. In addition to effects on whole-body metabolism,
there is a growing body of evidence to support the hypothesis
that ghrelin exerts effects on the cardiovascular system, and in
particular, directly on cardiomyocytes. In fact, ghrelin is synthe-
sized in and secreted from human cardiomyocytes [6], binds in
a speciﬁc and saturable manner to human left ventricular tis-
sue [8], and stimulates contractility in isolated rat ventricular
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myocytes through increasing Ca2+ current via GHS-R [26]. Addi-
tionally, ghrelin administration inhibits cardiomyocyte apoptosis
[1] and promotes differentiation of human embryonic stem cells to
mature cardiomyocytes through the extracellular signal-regulated
kinase (ERK 1/2) signaling pathway [4], but it is not clear if these
effects are mediated through GHS-R.
The expression of GHS-R itself may  reﬂect the progression of
cardiac pathology. GHS-R expression is up-regulated in left ven-
tricular tissue from patients with congestive heart failure [3] and
atherosclerosis [8], as well as in the hearts of rats during the hyper-
dynamic phase of sepsis [28]. These results indicate that GHS-R
signaling is altered in cardiovascular disease, and point toward the
use of ghrelin in pharmacologic therapy of heart disease. There-
fore, given the importance of GHS-R signaling and expression in the
heart, we are developing ghrelin analogs for the purpose of gener-
ating agents for in situ and in vivo imaging of cardiac GHS-R. We
have previously designed a ﬂuorescent ghrelin analog consisting
of a ﬂuorescein moiety attached through a lysine to the N-terminal
18 amino acids of ghrelin (ﬂuorescein-ghrelin(1–19)) [20] and have
shown that it speciﬁcally binds to GHS-R1a in mouse heart tissue.
0196-9781/$ – see front matter © 2014 Published by Elsevier Inc.
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While this analog can be used in ﬁxed cells and tissues, ﬂuorescein is
not useful for in vivo imaging, due to its propensity to photobleach,
its lack of depth penetration and high degree of tissue autoﬂuo-
rescence in the ﬂuorescein excitation wavelength. To obviate these
issues, we report in the present study the synthesis and character-
ization of a far-red probe, Cy5-ghrelin(1–19), and demonstrate its
use in tracking GHS-R expression in live differentiating cardiomy-
ocytes.
2. Materials and methods
2.1. Synthesis of Cy5-ghrelin and Cy5-des-acyl ghrelin
2.1.1. [Dpr3(octanoyl)Lys19(Cy5)]ghrelin (1–19)
The 19 amino acid analog of ghrelin, GS-Dpr-
FLSPEHQRVQQRKESK-amide, was synthesized using an automated
peptide synthesizer on Rink Amide MBHA resin (0.1 mmol). All
amino acids bear standard protecting groups with the exception
of residue 3, diaminopropanoic acid (Dpr), and residue 19, lysine,
that contain orthogonal side chain protecting groups allyloxycar-
bonyl (alloc) and 4-methyltrityl (mtt), respectively. While still on
resin, Dpr3(alloc) was selectively deprotected with phenylsilane
(2 mmol, 247 L) and tetrakis(triphenylphosphine)palladium (0)
(0.035 mmol, 40 mg)  under nitrogen. The resulting free amine was
coupled to octanoic acid (0.3 mmol, 247 L) using standard FMOC
procedures. Lys19(mtt) was selectively deprotected using 2% triﬂu-
oroacetic acid, 5% triisopropylsilane in dichloromethane, followed
by coupling to Cy5 succinimidyl ester (0.025 mmol, 19 mg)  in the
presence of N,N-diisopropylethylamine (0.6 mmol, 100 L). Once
fully functionalized, Dpr3(octanoyl), Lys19(Cy5) ghrelin (1–19)
was cleaved from the resin using 95% triﬂuoroacetic acid, 2.5%
triisopropylsilane and 2.5% water (2 mL). The crude peptide was
precipitated using ice cold tert-butylmethylether (20 mL)  and the
dark blue crude solid was then isolated by centrifugation. The solid
was dissolved in 10% acetonitrile in water, frozen in dry ice and
lyophilized overnight to yield a dark blue powder. Puriﬁcation was
performed by reverse-phase C18 HPLC (gradient 25–60% MeCN in
water) to obtain a 7% yield (5.1 mg)  of blue powder (89% purity).
Mass spectrometry electrospray ionization (MS  (ESI)): m/z calcd
1489.2, found 1489.4 [M+2H]2+.
2.1.2. Des-acyl [Lys19(Cy5)]ghrelin (1–19)
The 19 amino acid control analog of ghrelin,
GSSFLSPEHQRVQQRKESK-amide, was synthesized using an
automated peptide synthesizer on Rink Amide MBHA resin with
all amino acids bearing standard protecting groups with the
exception of residue 19, lysine, which is protected by the orthog-
onal protecting group, 4-methyltrityl. Lys19(mtt) is selectively
deprotected using 2% triﬂuoroacetic acid, 5% triisopropylsilane in
dichloromethane, followed by coupling to Cy5 succinimidyl ester
(0.025 mmol, 19 mg)  in the presence of N,N-diisopropylethylamine
(0.6 mmol, 100 L). Once fully functionalized, [Lys19(Cy5)]ghrelin
(1–19) was cleaved from the resin using 95% triﬂuoroacetic acid,
2.5% triisopropylsilane and 2.5% water (2 mL). The crude peptide
was precipitated using ice cold tert-butylmethylether (20 mL)  and
the dark blue crude solid was isolated by centrifugation. The solid
is dissolved in 10% acetonitrile in water, frozen in dry ice and
lyophilized overnight to yield a dark blue powder. Puriﬁcation was
performed by reverse-phase C18 HPLC (gradient 20–60% MeCN in
water) to obtain a 7% yield (4.8 mg)  of blue powder (97% purity).
MS (ESI): m/z calcd 1426.6, found 1427.0 [M+2H]2+.
2.2. Receptor binding assays
HEK293 cells (a kind gift from Dr. Andy Babwah, Western Uni-
versity) were grown in MEM  supplemented with non-essential
amino acids solution and 10% fetal bovine serum (FBS; Life Tech-
nologies). To generate HEK293/GHS-R1a cells, cells were grown
to 70% conﬂuency in a 75 cm ﬂask and transfected with GHS-
R1a-pcDNA3.1 plasmid (Missouri S&T cDNA Resource Center;
www.cdna.org) using a modiﬁed calcium phosphate transfection
procedure [21]. Receptor binding was measured by the compet-
itive binding of [125I] ghrelin with increasing concentrations of
the synthesized Cy5-ghrelin analogs using a previously published
method [23]. Brieﬂy, cells were harvested 48 h after transfection
and frozen at a concentration of 2 × 106 cells/mL. On the day of the
experiment, cells were thawed at room temperature, pelleted by
centrifugation and resuspended in binding buffer (25 mM HEPES,
5 mM MgCl2, 1 mM CaCl2, 2.5 mM EDTA, 0.4% BSA, plus mini com-
plete protease inhibitor (Roche), pH 7.4). Approximately 50,000
cells were incubated for 20 min  at 37 ◦C in binding buffer, 15 pM
[125I] ghrelin (Perkin Elmer) and increasing concentrations of each
Cy5-ghrelin analog (10−10–1 × 10−5 M).  Cells were pelleted, rinsed
with ice-cold 50 mM Tris–HCl (pH 7.4) to remove unbound activ-
ity and radioactivity was determined in a gamma counter. Binding
curves and IC50 values determined using GraphPad Prism 5 soft-
ware (San Diego, CA) as previously described [20]. Each sample
was analyzed in triplicate and assays were repeated twice for each
Cy5-ghrelin analog.
2.3. Live imaging of Cy5-ghrelin(1–19) in HEK293/GHS-R1a cells
HEK 293 cells were transiently transfected with the cDNA
encoding GHS-R1a in order to visualize the binding of Cy5-
ghrelin(1–19) in situ. Both wt HEK and HEK/GHS-R1a cells
were plated at a density of 1 × 106 cells/well in a 6-well plate,
and serum starved overnight. The following day, 10 M Cy5-
ghrelin(1–19) or 10 M Cy5-des-acyl ghrelin(1–19) was added
to the dishes (500 L/well), and cells were incubated at 37 ◦C
for 30 min, and subsequently rinsed in serum-free media. For
blocking studies, HEK/GHS-R1a cells were incubated with 10 M
Cy5-ghrelin(1–19) in the presence of 40 M unlabeled ghrelin
(1–28). Live cell images were captured using an inverted ﬂu-
orescent microscope and ﬁnal images were prepared using
ImageJ.
2.4. Binding of Cy5-ghrelin(1–19) and Cy5-des-acyl
ghrelin(1–19) to heart tissue in situ
Mice were treated in accordance with the guidelines set by
the Animal Use Subcommittee of the Canadian Council on Ani-
mal  Care at Western University. Adult male or female C57BL/6
mice were sacriﬁced using CO2 and the hearts were imme-
diately removed and ﬁxed in 4% paraformaldehyde (in PBS)
overnight. Whole hearts were then equilibrated in 30% sucrose in
PBS, snap-frozen in Tissue-Tek OCT using dry-ice cooled ethanol,
and subsequently cryosectioned at 8 m.  To assess binding of
both acylated and non-acylated ghrelin, sections were incubated
for 30 min  at room temperature with various concentrations
(0–20 M)  of Cy5-ghrelin(1–19) or Cy5-des-acyl ghrelin(1–19)
alone. To determine the speciﬁcity of binding, sections were incu-
bated with 10 M Cy5-ghrelin(1–19) and either 100 M ghrelin
(1–28) or 100 M hexarelin. Slides were then rinsed 3 × 5 min
in PBS, incubated in Hoechst 34445 as previously described [19]
to visualize nuclei, and mounted with glass coverslips. Slides
were viewed under a ﬂuorescent microscope using the Cy5 and
DAPI ﬁlters. Five random ﬁelds of view were captured for each
of 5 slides per tissue per mouse. Average ﬂuorescence inten-
sities were determined using ImageJ, as described previously
[18].
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Fig. 1. Structures of Cy5-ghrelin analogs. (A) Structure of wild-type human ghrelin, showing the octanoyl modiﬁcation on the side chain of Ser3. (B) Structure of
[Dpr3(octanoyl), Lys19(Cy5)]ghrelin (1–19). The 19 amino acid analog of ghrelin, GS-DprFLSPEHQRVQQRKESK-amide, was  synthesized using Dpr3 in place of Ser3. The
Cy5  moiety was  coupled to Lys19. (C) Structure of des-acyl [Lys19(Cy5)]ghrelin (1–19). The Ser3 bears no octanoyl modiﬁcation.
2.5. Differentiation of P19 cells and live cell imaging
P19 embryonic carcinoma cells were purchased from ATCC, and
grown in alpha-MEM/10% FBS (Life Technologies). To track differ-
entiation, P19 cells were stably transfected with a cDNA construct
designed to drive RFP expression only in differentiated cardiomy-
ocytes, as follows: the alpha myosin heavy chain (MHC) promoter
region (kind gift from Dr. J. Robbins, Cincinnati Children’s Hospital)
was fused to the ﬂuc-mrfp-sr39tk trifusion reporter (TFR) fragment
[24] (kind gift from Dr. S. Gambhir, Stanford) in the pBS vector (L.
Hoffman, unpublished results). The resulting plasmid, pBS/MHC-
TFR, was digested with Not1 restriction enzyme to release the
MHC-TFR sequence, which was then inserted into the Not1
restriction sites of pcDNA3.1. Correct orientation of the fragment
was conﬁrmed by sequencing. The pcDNA3.1/MHC-TFR construct
was transfected into P19 cells using Lipofectamine 2000 (Life
Technologies) and cells were selected for 3 weeks in 400 g/mL
hygromycin B (Life Technologies). For differentiation, spontaneous
aggregation of P19 cells was performed by passaging the cells into
10 cm dishes coated with 0.1% agarose/alpha-MEM/10% FBS/0.8%
DMSO to prevent adhesion of the cells. On day 4, embryoid bod-
ies (cell aggregates) were transferred to 6-well cell culture dishes
containing coverslips coated with 0.2% gelatin, and were main-
tained in alpha-MEM/10% FBS/0.8% DMSO. Medium was refreshed
every 48 h. Beating cardiac myocytes were ﬁrst observed at day
15 and by day 25 approximately 10% of the cells were beating
synchronously.
For live imaging of GHS-R, P19 cells at several time points
of differentiation (day 0, day 15 and day 28) were plated at a
density of 1 × 106 cells/well in a 6-well plate, and serum starved
overnight. The following day, 10 M Cy5-ghrelin(1–19) alone, or
with 100 M ghrelin (1–28) for blocking studies, was  added to the
dishes and cells were incubated at 37 ◦C for 30 min, and subse-
quently rinsed in serum-free media. Live cell images were captured
in the RFP (excitation 563 nm/emission 582 nm) and Cy5 (excitation
650 nm/emission 670 nm)  wavelengths using an inverted ﬂuores-
cent microscope and ﬁnal images were prepared using ImageJ
(National Institutes of Health, Bethesda, MD). Brightness and con-
trast were adjusted to improve image quality, and was  equally
applied to all pixels across all images. To amplify areas of coin-
cident pixels and reduce background, the RFP and Cy5 images
at day 25 were multiplied in ImageJ and green pseudocolor was
applied.
2.6. Western Blot analysis
Immediately after the imaging session, cells were rinsed 2× in
PBS and lysed in 0.5 mL  ice-cold phospho-safe extraction reagent
(EMD Millipore) plus mini complete protease inhibitor cocktail for
Western Blot analysis, as previously described [17]. Fifty micro-
grams of protein were separated on a 4–12% gradient NuPAGE
gel (Life Technologies), transferred to nitrocellulose membranes
and the following antibodies were used: anti-GHS-R1a (Abcam,
1:1000); and anti-GAPDH (Abcam, 1:1000) to assess protein load-
ing. Bands were visualized using SuperSignal chemiluminescent
substrate (Pierce) and images were captured using GeneSnap soft-
ware, as described previously [17].
2.7. Immunohistochemistry for differentiation markers
In parallel experiments, P19 cells at the same time points of
differentiation were ﬁxed and processed for immunohistochem-
istry, as described previously [16] using the following antibodies:
anti-connexin 43 (Sigma, 1:100), anti-cardiac troponin (Abcam,
1:100) and anti-SERCA 2a (Abcam, 1:100) at days 15 and 28.
Alexa 488-IgG (Life Technologies, 1:500) was used to visual-
ize cx-43 antibody, Alexa 647-IgG (1:500) was used to visualize
the c-troponin antibody, and Alexa 594-IgG (1:500) was used to
visualize the SERCA 2a antibody. Images were captured and recon-
structed using deconvolution microscopy as described previously
[18]. Regions containing both non-beating and beating cells were
captured from 5 ﬁelds of view from each of 3 wells per time
point.
2.8. Statistical analysis
For quantiﬁed images, a one-way ANOVA followed by a post hoc
Student’s t-test was used to determine statistical signiﬁcance. For
comparisons of binding at varying concentrations of peptide, a two-
way ANOVA and Student’s t test were used. Signiﬁcance was set at
p < 0.05.
84 G.A.F. Douglas et al. / Peptides 54 (2014) 81–88
3. Results
3.1. Receptor binding assays in HEK–GHS-R cells
We  characterized the binding of both Cy5-ghrelin and Cy5-
des-acyl ghrelin to GHS-R1a (structures shown in Fig. 1) with an
in vitro binding assay using HEK 293 cells over-expressing GHS-
R1a that we generated. Table 1 shows that the binding afﬁnity of
Cy5-ghrelin to GHS-R1a was within an order of magnitude of that
of wild-type ghrelin, and comparable to our previously reported
value for ﬂuorescein-ghrelin(1–19) [20]. In contrast, Cy5-des-acyl
ghrelin did not show any appreciable binding to GHS-R1a.
3.2. Microscopy in live HEK–GHS-R cells with block and without
receptor and with des-acyl ghrelin
To assess the speciﬁcity of Cy5-ghrelin for imaging GHS-R1a,
HEK/GHS-R1a cells were incubated with Cy5-ghrelin alone or in
the presence of excess ghrelin, and imaged with ﬂuorescence
microscopy. The robust ﬂuorescence observed in HEK/GHS-R1a
cells incubated with Cy5-ghrelin (Fig. 2, panel A) was  completely
abrogated by ghrelin (panel B), indicating displacement from
GHS-R1a. Further conﬁrmation of the speciﬁcity of binding was
demonstrated by the lack of ﬂuorescence in wild-type HEK cells
(Fig. 2, panel C). Localized ﬂuorescence, suggestive of receptor bind-
ing and internalization, was detected in cells expressing GHS-R1a
(Fig. 2, panel D).
Table 1
Receptor binding afﬁnities for ghrelin analogs.
Peptide IC50 (nM)
Ghrelin (1–28) 2.5 ± 1
Fluorescein-ghrelin(1–19) 9.5 ± 2.6a
Cy5-ghrelin(1–19) 25.8 ± 3.4
Cy5-des-acyl ghrelin(1–19) >1000
Values are means from two experiments.
a From Ref. [18].
3.3. Images of mouse heart tissue sections with block and with
des-acyl ghrelin
We  then characterized the binding of Cy5-ghrelin and Cy5-
des-acyl ghrelin to sections of mouse cardiac tissue. Although
Cy5-des-acyl ghrelin did not bind GHS-R1a, there are reports
of des acyl ghrelin binding to and inducing signaling in isolated
cardiomyocytes [1,10], so we investigated the use of the Cy5-des-
acyl ghrelin to visualize its binding to heart tissue. As expected,
tissue sections incubated with 10 M Cy5-ghrelin showed robust
ﬂuorescence, which was almost completely displaced by excess
ghrelin (Fig. 3A). In contrast, Cy5-des-acyl ghrelin showed no
binding to mouse cardiac tissue at the same concentration as
Cy5-ghrelin. In order to further investigate the binding of both
Cy5-ghrelin and des-acyl ghrelin to murine cardiac tissue, sections
were incubated with increasing concentrations of both peptides,
and the ﬂuorescence intensity was  quantiﬁed. Cy5-ghrelin bound
Fig. 2. Cy5-ghrelin binds in a speciﬁc manner to GHS-R1a. (A) Live HEK 293/GHS-R1a cells were incubated with 10 M Cy5-ghrelin(1–19) for 30 min, and subsequently rinsed
in  serum-free media and live cell images were captured. (B) Live HEK/GHS-R1a cells were incubated with 10 M Cy5-ghrelin(1–19) in the presence of 40 M unlabeled ghrelin
(1–28).  There was  no ﬂuorescence in the presence of unlabeled ghrelin. (C) Live wt HEK 293 cells were incubated with 10 M Cy5-ghrelin(1–19) for 30 min. No binding of
Cy5-ghrelin was  observed, indicating that no nonspeciﬁc binding occurred. Images are representative of 10 ﬁelds of view per well (n = 3). Scale bar for A–C is 100 m. (D)
High-magniﬁcation image of a HEK 293/GHS-R1a cell incubated with 10 M Cy5-ghrelin(1–19) for 30 min. Localized Cy5 ﬂuorescence is suggestive of membrane binding
and  internalization (arrows). Scale bar is 10 m.
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Fig. 3. Cy5-ghrelin binds to GHS-R1a on mature mouse cardiomyocytes. Frozen embedded mouse hearts were cryosectioned at 8 m. (A) Sections were incubated with 10 M
Cy5-ghrelin(1–19) alone (panel A), or in the presence of 100 M ghrelin (1–28) (panel B) to determine the speciﬁcity of binding. Unlabeled ghrelin prevented the binding of
Cy5-ghrelin. In panel C, sections were incubated with 10 M Cy5-des-acyl ghrelin(1–19) alone, which resulted in very little ﬂuorescence. Images are representative of ﬁve
random ﬁelds of view for each of 5 slides per tissue per mouse (n = 4). Scale bar for all images is 20 m.  (B) Sections were incubated for 30 min with various concentrations
(0–50  M) of Cy5-ghrelin(1–19) or Cy5-des-acyl ghrelin(1–19) alone. Mean ﬂuorescence intensity increased dramatically with increasing concentrations of Cy5-ghrelin, but
did  not increase signiﬁcantly with increasing concentrations of Cy5-des-acyl ghrelin. Values are mean ± SEM (n = 4). *p < 0.01 between Cy5-ghrelin and Cy5-des-acyl ghrelin.
SEM  bars are present on all data points, but may  be too small to be visualized in some cases.
murine cardiac tissue in a concentration-dependent manner,
whereas Cy5-des-acyl ghrelin showed greatly reduced binding at
the same concentrations (Fig. 3B).
3.4. Using Cy5-ghrelin to detect GHS-R expression during
differentiation
Having determined that Cy5-ghrelin binds to adult mouse car-
diac tissue via GHS-R1a, we investigated its utility in detecting
changes in GHS-R1a expression during cardiac differentiation. The
P19 cell line is an embryonic carcinoma cell line that can be
induced to differentiate into beating cardiomyocytes by treatment
with DMSO [7] (Suppl. Video 1). In order to track differentiation
over time, we transfected cells with a trifusion imaging reporter
gene containing RFP whose expression is driven by the MHC
promoter. Since MHC  transcription is activated only in mature
cardiomyocytes, RFP ﬂuorescence should be detectable only in
fully differentiated cells. In live P19 cells, there is no RFP signal
in scattered, undifferentiated cells at day 0, very weak ﬂuores-
cence in non-beating embryoid bodies at day 15 and very robust
ﬂuorescence in beating cardiomyocytes at day 25 (Fig. 4), thus
demonstrating differentiation in live cells. These same cells were
also incubated with Cy5-ghrelin. Interestingly, a few cells showed
Cy5 ﬂuorescence at day 15, before RFP ﬂuorescence was  detectable.
However, there was strong Cy5 ﬂuorescence at day 25, and that
pattern of Cy5 ﬂuorescence coincided with that of RFP, as demon-
strated when the RFP and Cy5 images were multiplied (Fig. 4). Both
RFP and Cy5 ﬂuorescence were seen at the stage where cells were
beating (Suppl. Videos 2 and 3).
3.5. P19 cells gain expression of GHS-R1a during induced
cardiomyocyte differentiation
To conﬁrm that P19 cells were differentiating and express-
ing GHS-R, cells treated with DMSO at day 0, day 15 and day
25 were assessed for GHS-R expression by Western Blot, and
cells were examined for expression of differentiation markers by
immunoﬂuorescence microscopy. There was no expression of GHS-
R1a at day 0, very faint expression at day 15, and robust expression
at day 25 (Fig. 5A), coinciding with Cy5-ghrelin imaging. We  then
examined cellular architecture using cardiac troponin as a marker
of cardiomyocyte differentiation and connexin-43 as an indicator
that cardiomyocytes were interconnected and forming a functional
syncitium. At day 15 after DMSO treatment, there was some deﬁned
and localized ﬂuorescence of cardiac troponin and connexin-43,
which appeared to increase at day 25 (Fig. 5B), indicating that cells
were differentiating to a cardiomyocyte phenotype. Finally, cells
were immunostained for SERCA 2a to mark the onset of contrac-
tility. Robust SERCA 2a immunoﬂuorescence was  observed only at
day 25 (Fig. 5B).
4. Discussion
Structure–activity relationship studies using varying lengths of
the peptide ghrelin have determined the minimum active core
that is responsible for ghrelin receptor afﬁnity [2,16,27]. Ghrelin
can be truncated to as small as a pentapeptide containing the ﬁve
N-terminal amino acid residues and still maintain high-afﬁnity
receptor binding. Additionally, the octanoyl modiﬁcation on the
side chain of Ser3 is crucial for binding activity as it acts like an
anchor, inserting itself into the ghrelin receptor and facilitating lig-
and binding [5]. In the native peptide this unique feature bears
an ester linkage to the octanoyl that is sensitive to ester hydrol-
ysis in vivo. In order to increase peptide stability, we replaced Ser3
with the unnatural amino acid diaminopropanoic acid (Dpr), which
replaces the ester linkage with an amide linkage. It has been shown
that this modiﬁcation results in improved stability while having no
effect on GHS-R1a binding afﬁnity [13]. We  have previously syn-
thesized two analogs of ghrelin, 14-mer and 19-mer, to incorporate
these important structural features as well as further modiﬁcations
to bear non-radioactive isotopes, 19F and Re [25] and an optical dye
[20]. Our results demonstrate the ﬂexibility permitted by the struc-
ture of ghrelin in designing molecules for imaging GHS-R1a. We
now report the synthesis of a 19-mer ghrelin analog containing the
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Fig. 4. Using Cy5-ghrelin to track GHS-R1a expression during cardiomyocyte differentiation. Live P19 cells expressing MHC-TFR were incubated with 10 M Cy5-
ghrelin(1–19) before (day 0) or after (day 15, day 28) addition of DMSO to induce differentiation into beating cardiomyocytes. In panels A–C, RFP ﬂuorescence is observed
only  at day 28. Cy5-ghrelin binds to a few cells at day 15 (panel E), and there is robust Cy5 ﬂuorescence at day 28 (panel F). Panels G and H show corresponding bright-ﬁeld
images. Images are representative of 5 ﬁelds of view in each of 3 wells of cells at each time point. To show areas of coincident RFP- and Cy5-positive pixels in the absence of
background, images at day 25 were multiplied in Image J (panel H). Scale bar for all images is 100 m.
ﬁrst 19 N-terminus residues with substitutions at Ser3(octanoyl)
to contain Dpr3(octanoyl), to replace the ester linkage, and Lys19
to integrate the far-red dye, Cy5. The binding of Cy5-ghrelin shows
strong afﬁnity for GHS-R1a and the IC50 value, while not as favor-
able as what we reported for ﬂuorescein ghrelin [20], is still in
the nanomolar range. Therefore, it appears that any organic ﬂu-
orescent dye can be incorporated at the C-terminus of truncated
ghrelin analogs while preserving high-afﬁnity binding to GHS-R1a.
Since structure–function studies indicate receptor binding is intact
down to 5-mer peptides, it may  be possible to develop GHSR imag-
ing agents with even lower molecular weight and with improved
stability for in vitro and in vivo use. Furthermore, these GHSR tar-
geted ligands could be appended to nanoparticles or other carrier
molecules for efﬁcient receptor targeting and improved imaging
signal.
The design of our Cy5-ghrelin analogs demonstrates the ability
to add any ﬂuorescent cyanine dye at Lys19, maintain receptor bind-
ing afﬁnity and have an emission wavelength appropriate for any
given study. Additionally, the photostability and negligible spectral
overlap between the Cy family of dyes permit two- or three-color
imaging, as has been done for single molecule FRET [11]. For exam-
ple, it might be interesting to use Cy3-ghrelin and Cy5-des acyl
ghrelin to simultaneously investigate binding sites on cardiomy-
ocytes. Alternatively, Cy7, whose emission and excitation spectra
are in the near-infrared range, can be conjugated to ghrelin using
our design for in vivo ﬂuoresence imaging.
Development of ﬂuorescent ghrelin analogs allowed us to inves-
tigate the binding of des-acyl ghrelin to GHS-R1a and to murine
cardiac tissue. Our results show that Cy5-des-acyl ghrelin does not
bind to GHS-R1a. These results are consistent with previous reports
that show that the octanoic acid modiﬁcation on Ser3 is required
for binding of ghrelin to GHS-R1a [2,15]. However, our results also
show that Cy5-des-acyl ghrelin does not bind to mouse heart tis-
sue in situ. These results are at variance with a report showing
two distinct binding sites for des-acyl ghrelin in HL-1 cells and
isolated murine cardiomyocytes [10]. An alternate explanation for
their binding data is that the abundance of low-afﬁnity binding
sites is much greater than that of high-afﬁnity binding sites. The
biphasic competitive binding curves suggests that this is indeed
the case. Moreover, binding of [125I-Tyr4]des-acyl ghrelin does not
appear to reach saturation, suggesting nonspeciﬁc binding or a high
dissociation rate. If the majority of des-acyl ghrelin binding sites on
cardiomyocytes are of low afﬁnity, this generally means a high dis-
sociation rate, and therefore the des-acyl binding site may  not be
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Fig. 5. GHS-R1a expression anticipates onset of cardiomyocyte contractility. (A) Cell lysates from P19/MHC-TFR cells were collected at the indicated time points. Fifty
micrograms of protein were separated on a 4–12% gradient SDS-PAGE gel and membranes were probed for GHS-R (upper panel) and GAPDH (lower panel). The images are
representative of two  independent experiments. (B) P19/MHC-TFR cells were grown and ﬁxed on coverslips at the indicated time points. Cells were incubated with the
indicated antibodies and images were collected from 5 ﬁelds of view from each of 3 coverslips. Note the elongated morphology of c-troponin staining in cells at day 25 after
differentiation. The expression of SERCA 2a coincides with the onset of beating, as shown in Supplemental Videos 1–3.
captured by the Cy5 ligand. The presence of the Cy5 moiety may  also
affect the binding of des-acyl ghrelin to such a low-afﬁnity recep-
tor. If the Cy5 moiety decreases des-acyl ghrelin binding afﬁnity by
8-fold, as is the case with octanoylated ghrelin, then is it entirely
possible that binding sites are not being detected. Therefore, Cy5-
des-acyl ghrelin may  be used as a tool to further investigate the
nature of the des-acyl ghrelin binding sites on cardiomyocytes, and
other tissues.
Using our ﬂuorescent ghrelin analog to examine cardiac GHS-R
expression will provide a useful tool in determining the distribution
and function of GHS-R in the normal mouse heart. A recent report
has described the use of a monoclonal antibody against GHS-R to
determine receptor distribution in primary rat hippocampal and
cortical neurons [9]. The ﬂuorescent peptide analogs could also be
used to map  GHS-R distribution in normal, developing and diseased
heart, both in situ and in vivo, and additionally, can be used to
determine the dynamics of receptor activation, such as internal-
ization and trafﬁcking. As well, the question of the roles of ghrelin
vs. des-acyl ghrelin in cardiomyocyte function can be examined.
Cardiomyocyte contraction in normal isolated cardiomyocytes and
inhibition of sympathetic activity appear to be mediated through
ghrelin activation of GHS-R1a [14,26]. Both actions could contribute
either directly or indirectly to the promotion of cardiomyocyte sur-
vival. However, in studies examining signaling pathways in survival
and differentiation, des-acyl ghrelin has the same anti-apoptotic
effects as ghrelin in an embryonic cardiomyocyte cell line H9c2
[1], and both ghrelin and des-acyl ghrelin promote differentiation
through ERK 1/2 activation in undifferentiated hESCs [4]. Inter-
estingly, that study showed that hESCs gradually express GHS-R
as they differentiate, similar to our results with P19 cells. There-
fore, our ﬂuorescent ghrelin probes will be useful in ascertaining
whether des-acyl ghrelin really does bind to stem cells or cardiac
progenitors in vivo to induce differentiation.
Another advantage of the Cy5-ghrelin analog is that it allows for
identiﬁcation of GHS-R expression at the individual cell level. By
Western Blot alone, GHS-R expression in P19-derived cardiomy-
ocytes is evident only after day 28 of differentiation. However,
imaging with Cy5-ghrelin shows deﬁned and discrete ﬂuorescence
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in a signiﬁcant number of cells at d15. These cells do not show
RFP ﬂuorescence, indicating that GHS-R expression precedes MHC
expression. Our results suggest that GHS-R may  be a marker of the
early stages of cardiomyocyte differentiation. In particular, since
GHS-R expression appeared before the cells started to beat, it may
be that the appearance of GHS-R1a presages the onset of contrac-
tility in cardiomyocytes.
In summary, we have synthesized a far-red analog of ghrelin
that binds speciﬁcally to GHS-R1a and to mature cardiomyocytes.
This analog can be used to track GHS-R expression during dif-
ferentiation in P19-derived cardiomyocytes. Studies using our
Cy5-ghrelin(1–19) imaging agent to determine GHS-R1a expres-
sion in differentiating and diseased cardiac tissue are currently
underway.
Acknowledgements
The authors would like to thank Mr.  Andrew Bondoc and Ms.
Linshin Liu for assisting with the deconvolution microscopy and
Western Blot analysis of GHS-R expression, respectively, and Mr.
Leonardo Guizzetti for assistance in image preparation. This work
was supported by grants from Western University (to S.D.), and the
Canadian Institutes for Health Research (to L.L.).
Appendix A. Supplementary data
Supplementary data associated with this article can be found,
in the online version, at http://dx.doi.org/10.1016/j.peptides.
2014.01.011.
References
[1] Baldanzi G, Filigheddu N, Cutrupi S, Catapano F, Bonissoni S, Fubini A, et al.
Ghrelin and des-acyl ghrelin inhibit cell death in cardiomyocytes and endothe-
lial  cells through ERK1/2 and PI 3-kinase/AKT. J Cell Biol 2002;159:1029–37.
[2] Bednarek MA,  Feighner SD, Pong SS, McKee KK, Hreniuk DL, Silva MV,  et al.
Structure–function studies on the new growth hormone-releasing peptide,
ghrelin: minimal sequence of ghrelin necessary for activation of growth hor-
mone secretagogue receptor 1a. J Med  Chem 2000;43:4370–6.
[3] Beiras-Fernandez A, Kreth S, Weis F, Ledderose C, Pottinger T, Dieguez C, et al.
Altered myocardial expression of ghrelin and its receptor (GHSR-1a) in patients
with severe heart failure. Peptides 2010;31:2222–8.
[4] Gao M,  Yang J, Wei  R, Liu G, Zhang L, Wang H, et al. Ghrelin induces cardiac lin-
eage differentiation of human embryonic stem cells through ERK1/2 pathway.
Int  J Cardiol 2012;167:2724–33.
[5] Grossauer J, Kosol S, Schrank E, Zangger K. The peptide hormone ghrelin binds
to membrane-mimetics via its octanoyl chain and an adjacent phenylalanine.
Bioorg Med  Chem 2010;18:5483–8.
[6] Iglesias MJ,  Pineiro R, Blanco M,  Gallego R, Dieguez C, Gualillo O, et al. Growth
hormone releasing peptide (ghrelin) is synthesized and secreted by cardiomy-
ocytes. Cardiovasc Res 2004;62:481–8.
[7] Jasmin, Spray DC, Campos de Carvalho AC, Mendez-Otero R. Chemical induction
of  cardiac differentiation in P19 embryonal carcinoma stem cells. Stem Cells
Dev 2010;19:403–12.
[8] Katugampola SD, Pallikaros Z, Davenport AP. [125I-His(9)]-ghrelin, a
novel radioligand for localizing GHS orphan receptors in human and rat
tissue: up-regulation of receptors with atherosclerosis. Br J Pharmacol
2001;134:143–9.
[9] Lattuada D, Crotta K, Tonna N, Casnici C, Benfante R, Fornasari D, et al. The
expression of GHS-R in primary neurons is dependent upon maturation stage
and regional localization. PLoS ONE 2013;8:e64183.
[10] Lear PV, Iglesias MJ,  Feijoo-Bandin S, Rodriguez-Penas D, Mosquera-Leal
A, Garcia-Rua V, et al. Des-acyl ghrelin has speciﬁc binding sites and
different metabolic effects from ghrelin in cardiomyocytes. Endocrinology
2010;151:3286–98.
[11] Lee S, Lee J, Hohng S. Single-molecule three-color FRET with both negligible
spectral overlap and long observation time. PLoS ONE 2010;5:e12270.
[12] Ma X, Lin L, Qin G, Lu X, Fiorotto M,  Dixit VD, et al. Ablations of ghrelin and
ghrelin receptor exhibit differential metabolic phenotypes and thermogenic
capacity during aging. PLoS ONE 2011;6:e16391.
[13] Maletinska L, Pychova M,  Holubova M,  Blechova M,  Demianova Z, Elbert T,
et al. Characterization of new stable ghrelin analogs with prolonged orexigenic
potency. J Pharmacol Exp Ther 2012;340:781–6.
[14] Mao  Y, Tokudome T, Otani K, Kishimoto I, Miyazato M,  Kangawa K. Excessive
sympathoactivation and deteriorated heart function after myocardial infarc-
tion in male ghrelin knockout mice. Endocrinology 2013;154:1854–63.
[15] Martin-Pastor M,  De Capua A, Alvarez CJ, Diaz-Hernandez MD,  Jimenez-Barbero
J,  Casanueva FF, et al. Interaction between ghrelin and the ghrelin recep-
tor  (GHS-R1a), a NMR  study using living cells. Bioorg Med  Chem 2010;18:
1583–90.
[16] Matsumoto M,  Hosoda H, Kitajima Y, Morozumi N, Minamitake Y, Tanaka
S,  et al. Structure–activity relationship of ghrelin: pharmacological study of
ghrelin peptides. Biochem Biophys Res Commun 2001;287:142–6.
[17] McGirr R, Ejbick CE, Carter DE, Andrews JD, Nie Y, Friedman TC, et al. Glu-
cose dependence of the regulated secretory pathway in alphaTC1-6 cells.
Endocrinology 2005;146:4514–23.
[18] McGirr R, Guizzetti L, Dhanvantari S. The sorting of proglucagon to secretory
granules is mediated by carboxypeptidase E and intrinsic sorting signals. J
Endocrinol 2013;217:229–40.
[19] McGirr R, Hu S, Yee SP, Kovacs MS,  Lee TY, Dhanvantari S. Towards PET imaging
of  intact pancreatic beta cell mass: a transgenic strategy. Mol  Imaging Biol
2011;13:962–72.
[20] McGirr R, McFarland MS,  McTavish J, Luyt LG, Dhanvantari S. Design and char-
acterization of a ﬂuorescent ghrelin analog for imaging the growth hormone
secretagogue receptor 1a. Regul Pept 2011;172:69–76.
[21] Pampillo M,  Camuso N, Taylor JE, Szereszewski JM,  Ahow MR,  Zajac M,  et al.
Regulation of GPR54 signaling by GRK2 and {beta}-arrestin. Mol  Endocrinol
2009;23:2060–74.
[22] Patterson ZR, Ducharme R, Anisman H, Abizaid A. Altered metabolic and
neurochemical responses to chronic unpredictable stressors in ghrelin
receptor-deﬁcient mice. Eur J Neurosci 2010;32:632–9.
[23] Pinyot A, Nikolovski Z, Bosch J, Segura J, Gutierrez-Gallego R. On the use of
cells or membranes for receptor binding: growth hormone secretagogues. Anal
Biochem 2010;399:174–81.
[24] Ray P, De A, Min  JJ, Tsien RY, Gambhir SS. Imaging tri-fusion multimodality
reporter gene expression in living subjects. Cancer Res 2004;64:1323–30.
[25] Rosita D, Dewit MA,  Luyt LG. Fluorine and rhenium substituted ghrelin ana-
logues as potential imaging probes for the growth hormone secretagogue
receptor. J Med  Chem 2009;52:2196–203.
[26] Sun Q, Ma Y, Zhang L, Zhao YF, Zang WJ,  Chen C. Effects of GH secretagogues on
contractility and Ca2+ homeostasis of isolated adult rat ventricular myocytes.
Endocrinology 2010;151:4446–54.
[27] Van Craenenbroeck M, Gregoire F, De Neef P, Robberecht P, Perret J. Ala-scan
of ghrelin (1–14): interaction with the recombinant human ghrelin receptor.
Peptides 2004;25:959–65.
[28] Wu R, Zhou M,  Cui X, Simms HH, Wang P. Upregulation of cardiovascular ghrelin
receptor occurs in the hyperdynamic phase of sepsis. Am J Physiol Heart Circ
Physiol 2004;287:H1296–302.
[29] Zigman JM,  Nakano Y, Coppari R, Balthasar N, Marcus JN, Lee CE, et al. Mice
lacking ghrelin receptors resist the development of diet-induced obesity. J Clin
Invest 2005;115:3564–72.
